GlassScriptPhysician profile
Beth Schorr-Lesnick
NPI 1720013139
$3,172.61
in general payments reported to CMS, 2019-2025
23 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $70.90 · 2021: $173 · 2022: $477 · 2023: $354 · 2024: $385 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,800.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $751.24 | 2019-2025 | Skyrizi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $396.87 | 2019-2025 | Entyvio, Livtencity, Gattex |
| Janssen Biotech, INC. | $371.41 | 2019-2025 | Stelara, Simponi, Tremfya |
| Qol Medical, LLC | $280.71 | 2023-2025 | Sucraid |
| Pfizer INC. | $268.54 | 2019 | |
| Gilead Sciences, INC. | $211.36 | 2019-2020 | |
| Madrigal Pharmaceuticals | $198.24 | 2025 | Rezdiffra |
| Celgene Corporation | $197.90 | 2022-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.75 | 2021-2024 | Xifaxan, Trulance, Plenvu |
| Aimmune Therapeutics, INC. | $59.95 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $46.37 | 2024-2025 | Omvoh |
| Genzyme Corporation | $39.74 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $39.54 | 2021 | |
| Alnylam Pharmaceuticals INC. | $31.92 | 2021-2025 | Givlaari |
| Ipsen Biopharmaceuticals, INC | $31.68 | 2025 | Iqirvo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $29.52 | 2025 | Wegovy |
| Amgen INC. | $29.05 | 2023 | Avsola, Amjevita |
| Ardelyx, INC. | $24.09 | 2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $22.47 | 2024 | |
| Ferring Pharmaceuticals INC. | $20.90 | 2023 | Rebyota |
| Celltrion USA INC. | $20.22 | 2024 | Zymfentra |
| Fujifilm Healthcare Americas Corporation | $16.59 | 2025 | |
| Merck Sharp & Dohme LLC | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Schorr-Lesnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.